| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | vincristine | CTRPv2 | pan-cancer | AAC | 0.063 | 0.04 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.094 | 0.04 |
| mRNA | methylstat | CTRPv2 | pan-cancer | AAC | 0.085 | 0.04 |
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | -0.07 | 0.05 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.059 | 0.05 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.05 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.091 | 0.05 |
| mRNA | necrosulfonamide | CTRPv2 | pan-cancer | AAC | 0.075 | 0.06 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.065 | 0.06 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.074 | 0.06 |